Skip to main content Skip to section navigation Skip to footer
Careers News & Media Contact
OPKO Health, Inc. OPKO Health, Inc.
  • Therapies
    • Overview
    • Ngenla
    • Rayaldee
  • Research
    • Overview
    • Pipeline
    • Publications
    • Scientific Presentations
  • Diagnostics
  • Company
    • Overview
    • Leadership
    • Locations
  • Partnerships
  • Investors
    • Overview
    • News / Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • News & Media
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 24, 2022 4:05pm EST

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

Feb 17, 2022 8:00am EST

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

Feb 15, 2022 11:30am EST

Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

Feb 03, 2022 8:30am EST

RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

Jan 21, 2022 8:00am EST

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

Jan 20, 2022 8:00am EST

JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

Jan 18, 2022 11:51am EST

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Jan 05, 2022 4:05pm EST

OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Dec 23, 2021 8:00am EST

OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

Dec 08, 2021 8:00am EST

OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 52
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137


T: 305-575-4100
contact@opko.com

©2025 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of use Sitemap